{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:35:54Z","timestamp":1782930954669,"version":"3.54.5"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01150","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T04:33:31Z","timestamp":1591331611000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":48,"title":["Management of Mevalonate Kinase Deficiency: A Pediatric Perspective"],"prefix":"10.3389","volume":"11","author":[{"given":"Jerold","family":"Jeyaratnam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Frenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1002\/art.39763","article-title":"The phenotype and genotype of mevalonate kinase deficiency: a series of 114 cases from the Eurofever registry","volume":"68","author":"ter Haar","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1002\/art.22194","article-title":"A role for geranylgeranylation in interleukin-1beta secretion","volume":"54","author":"Mandey","year":"2006","journal-title":"Arthritis Rheumatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/ni.3457","article-title":"Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS","volume":"17","author":"Park","year":"2016","journal-title":"Nat Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1126\/science.1254790","article-title":"Inflammation","volume":"345","author":"Reboldi","year":"2014","journal-title":"Science."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1136\/ard.2004.023697","article-title":"EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees","volume":"63","author":"Dougados","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1056\/NEJMoa070715","article-title":"Allogeneic bone marrow transplantation in mevalonic aciduria","volume":"356","author":"Neven","year":"2007","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJMc072018","article-title":"Mevalonic aciduria cured by bone marrow transplantation","volume":"357","author":"Arkwright","year":"2007","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00296-016-3456-9","article-title":"Massive ascites in a canakinumab resistant case with MVA leading to bone marrow transplantation","volume":"36","author":"Erdol","year":"2016","journal-title":"Rheumatol Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.clpt.2004.01.012","article-title":"Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome","volume":"75","author":"Simon","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"B10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00005792-199405000-00002","article-title":"Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group","volume":"73","author":"Drenth","year":"1994","journal-title":"Medicine."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.jaci.2019.02.013","article-title":"Lack of protein prenylation promotes NLRP3 inflammasome assembly in human monocytes","volume":"143","author":"Skinner","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41419-019-1413-8","article-title":"Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors","volume":"10","author":"Yang","year":"2019","journal-title":"Cell Death Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1136\/ard.2011.149922","article-title":"On-demand anakinra treatment is effective in mevalonate kinase deficiency","volume":"70","author":"Bodar","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3899\/jrheum.170684","article-title":"Efficacy of continuous interleukin 1 blockade in mevalonate kinase deficiency: a multicenter retrospective study in 13 adult patients and literature review","volume":"45","author":"Deshayes","year":"2018","journal-title":"J Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the treatment of autoinflammatory recurrent fever syndromes","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/acr.23120","article-title":"International retrospective chart review of treatment patterns in severe familial mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, and mevalonate kinase deficiency\/hyperimmunoglobulinemia D syndrome","volume":"69","author":"Ozen","year":"2017","journal-title":"Arthritis Care Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/01.RHU.0000442576.41537.de","article-title":"Interleukin 6 blockade for hyperimmunoglobulin d and periodic fever syndrome","volume":"20","author":"Shendi","year":"2014","journal-title":"J Clin Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"bcr2015210513","DOI":"10.1136\/bcr-2015-210513","article-title":"Anti-interleukin 6 receptor therapy for hyper-IgD syndrome","volume":"2015","author":"Musters","year":"2015","journal-title":"BMJ Case Rep."},{"key":"B19","first-page":"S46","article-title":"Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature","volume":"33","author":"Lane","year":"2015","journal-title":"Clin Exp Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/MD.0b013e318190cfb7","article-title":"Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome","volume":"87","author":"Van Der Hilst","year":"2008","journal-title":"Medicine."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01150\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T04:33:33Z","timestamp":1591331613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01150\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2020.01150"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01150","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"article-number":"1150"}}